LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Assay Detects Clostridium difficile Toxin B Gene

By LabMedica International staff writers
Posted on 01 Dec 2008
A molecular assay rapidly detects the toxin B gene found in toxigenic Clostridium difficile, the bacterial pathogen responsible for C. difficile infection (CDI). It is the first CDI molecular diagnostic that offers sensitivity, simplicity, and speed in one test procedure.

The test, performed directly from stool specimens, targets the toxin B gene found in toxigenic C. difficile strains, including the BI/NAP1/027 epidemic strain associated with a major CDI outbreak in 2003. It can lead to a definitive diagnosis in less than two hours and may facilitate earlier and more appropriate antibiotic treatment of CDI patients. It may also lead to earlier implementation of infection controls.

Becton, Dickinson and Company (BD; Franklin Lakes, NJ, USA) has added this test, which is called the GeneOhm Cdiff assay, to its expanding menu of rapid molecular tests to help prevent healthcare-associated infections, including tests for Staphylococcus aureus and methicillin-resistant S. aureus (MRSA). In addition, BD recently submitted a test to detect the resistant genes associated with vancomycin-resistant Enterococci to Health Canada (Ottawa, ON, Canada) for licensure.

Until now, diagnosing CDI rapidly has proven difficult. Traditional methods, including immunoassays, lack sufficient sensitivity, while tissue culture cytotoxicity methods are difficult to perform and require several days to yield results.

BD announced that Health Canada has licensed the new BD GeneOhm: "Clostridium difficile poses a significant challenge for healthcare facilities across Canada," said Jay Glasscock, Vice President and General Manager, BD in Canada. "We applaud Health Canada for fast-tracking the licensing of this important new test, which will help provide more definitive and more rapid diagnoses of CDI patients. The BD GeneOhm Cdiff assay was developed by BD research scientists in Quebec and will be produced in our new manufacturing facility in Parc Technologique du Quebec Metropolitain."

Related Links:
Becton, Dickinson and Company
Health Canada



New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Repetitive Pipette
VWR® Stepper Pro

Latest Molecular Diagnostics News

Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
01 Dec 2008  |   Molecular Diagnostics

Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
01 Dec 2008  |   Molecular Diagnostics

Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
01 Dec 2008  |   Molecular Diagnostics



ADLM